A MALT lymphoma prognostic index-Reference-Cited by-同舟云学术

A MALT lymphoma prognostic index

Published:2017-09-21 Issue:12 Volume:130 Page:1409-1417
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Thieblemont Catherine¹,Cascione Luciano²³,Conconi Annarita³⁴,Kiesewetter Barbara⁵,Raderer Markus⁵,Gaidano Gianluca⁶,Martelli Maurizio⁷,Laszlo Daniele⁸,Coiffier Bertrand⁹,Lopez Guillermo Armando¹⁰,Torri Valter¹¹,Cavalli Franco²³,Johnson Peter W.¹²,Zucca Emanuele²³

Affiliation:

1. Assistance Publique–Hôpitaux de Paris Hemato-Oncology Department, Saint Louis Hospital, Diderot University–Sorbonne Paris Cité, Paris, France;

2. Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;

3. Institute of Oncology Research, Bellinzona, Switzerland;

4. Unit of Hematology, Ospedale degli Infermi, Biella, Italy;

5. Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria;

6. Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Ospedale Maggiore della Carità, Novara, Italy;

7. Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;

8. European Institute of Oncology, Milan, Italy;

9. Centre Hospitalier Lyon-Sud, Pierre-Benite, France;

10. Department of Haematology, Hospital Clinic, Barcelona, Spain;

11. Clinical Research Methodology Laboratory, IRCCS–Mario Negri Institute, Milan, Italy; and

12. Cancer Research UK Center, Southampton General Hospital, Southampton, United Kingdom

Abstract

Key Points The MALT-IPI was built by using 401 patients in the IELSG-19 randomized trial and validated in an independent set (N = 633). This novel disease-specific index efficiently discriminates patient with good, intermediate, and poor outcomes.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/12/1409/1402713/blood771915.pdf

Reference42 articles.

1. A predictive model for aggressive non-Hodgkin’s lymphoma;International Non-Hodgkin’s Lymphoma Prognostic Factors Project;N Engl J Med,1993

2. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP;Sehn;Blood,2007

3. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era;Zhou;Blood,2014

4. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France;Foussard;Ann Oncol,1997

5. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma;López-Guillermo;J Clin Oncol,1994

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of serum monoclonal proteins based on immunofixation electrophoresis in B-cell non-Hodgkin lymphoma;Annals of Hematology;2023-12-20

2. Treatment and Survival for Patients with Localized Primary Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma;2023-12-04

3. Long-Term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Study;Acta Haematologica;2023-11-24

4. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study;Blood Advances;2023-11-15

5. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study;Blood Advances;2023-11-15